Navigation Links
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
Date:6/10/2009

tion of the nonclinical profile of INT131 into the clinic is an exciting validation of the selective PPAR modulator design of the molecule," added Dr Linda Higgins, Chief Scientific Officer of InteKrin Therapeutics. "INT131 retains or exceeds TZD potency and efficacy for glycemic lowering in rodent models of T2DM, while also showing remarkable safety in nonclinical studies of INT131 even at multiples of clinical exposures that far exceed those at which toxicities are observed with TZDs."

These Phase 2a study data provided the rationale for a double blind placebo controlled 24 week Phase 2b study of 4 doses of INT131 and 45 mg Actos(R) as active comparator in 360 T2DM patients. InteKrin completed enrollment of the study in March, 2009.

About INT131

INT131 is a next-generation, non-TZD insulin sensitizer and selective modulator of PPARgamma (SPPARM). INT131 belongs to a unique, non-TZD chemical class, and was purposely designed to retain the well validated and robust insulin sensitizing efficacy of PPARgamma while minimizing the typical side effects seen with the full agonists TZDs Actos(R) and Avandia(R). PPARgamma activation treats insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, t
'/>"/>

SOURCE InteKrin Therapeutics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. InteKrin Therapeutics Announces $20 Million Series C Financing
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
8. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
9. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
10. Cephalon Acquires Controlling Interest in Arana Therapeutics
11. Cornerstone Therapeutics Announces Management Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... New York, NY (PRWEB) November 24, 2014 ... performance, the progressive world of fitness technology will take center ... Living in Digital Times at the 2015 International ... 5:00pm in the Venetian, Level 2, Bellini 2004). The bond ... industry evolves into being less about devices and more about ...
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... 24, 2014 Olaparib functions as a ... and is one of the first PARP inhibitors. Sufferers ... some types of melanoma, and are often immune to ... gives their malignancies a exclusive weaknesses, as the tissues ... their DNA and allow them to proceed splitting. This ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... ER visits and additional imaging services , CHICAGO, ... quickly could cut by half the amount paid for hospital ... Clinical Congress of the American College of Surgeons. According to ... gallstones at the University of North Carolina in 2008, the ...
... onerous, futile medical interventions are ordered for these end-stage ... -- Many people see end-stage dementia as affecting only ... disease,s effects are far-reaching and eventually fatal. , ... not a terminal condition can have negative ...
... ... organization (PPO) plans in Albany, Essex, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties, ... Medicare Choices individual PPO plans now serve Medicare-eligibles in 23 counties, while its group ... ...
... between brain and device , WEDNESDAY, Oct. 14 (HealthDay ... connections between prosthetic hands and the brain, potentially paving ... type, sense hot and cold, and touch others. , ... "would allow people to have a prosthetic that functions ...
... 14 The National Women,s Law Center,s (NWLC) groundbreaking ... Health Insurance Market Fails Women," first released in ... discriminates against women. Now, this ground-breaking research has resulted ... signed by Governor Schwarzenegger over the weekend -- that ...
... Oct. 14 The Guardian Life Insurance Company of America ... leading provider of employee and voluntary benefits for small and ... products and their sales force according to a study conducted ... that Guardian received "very good to excellent" ratings on all ...
Cached Medicine News:Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 2Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 3Health News:Families Need to Know When Dementia Becomes Terminal 2Health News:Families Need to Know When Dementia Becomes Terminal 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 2Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 4Health News:Fine-Tuning Prosthetic Hands to Restore a Sense of Touch 2Health News:National Women's Law Center Challenges Insurance Industry Practices That Treat Being a Woman Like a 'Pre-Existing Condition' 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 3
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
(Date:11/24/2014)... Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... , President and CEO of Inovio Pharmaceuticals, will be joined ... ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, ... th listing on the Nasdaq Global Select Market.  ... said, "We are honored to ring the Nasdaq Opening Bell ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
UroPass Open Tip Ureteral Stents perfect over-the-wire placement with a combination of flexibility and rigidity for comfort and control. When it comes to stent designs, UroPass is a proven leader....
... proper patient position during surgery is key ... ophthalmic procedures. Not every patient is able ... slight movements can compromise the procedure or ... The Rousseau chin-lift stabilizer eliminates the "drifting ...
The Pathfinder HSV 1 and 2 kit provides direct antigen detection and differentiation of Herpes Simplex Virus (HSV) Types 1 and 2. The monoclonal antibody-based test can be used to directly stain cli...
... Demonstration of rubella IgG antibody in women ... protection from possible rubella viral infection during ... has greatly reduced the incidence of rubella ... accurate monitoring of immune status, especially for ...
Medicine Products: